Key terms
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Worcester, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MBIO news
Mar 28
9:10am ET
Mustang Bio announces vision for CAR T-Cell therapy platform expansion
Mar 15
5:26pm ET
Mustang Bio files to sell common stock, warrants, no amount given
Mar 13
6:10am ET
Analysts Offer Insights on Healthcare Companies: iCAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)
Mar 07
7:34am ET
Mustang Bio announces publication of data from Phase 1 trial of MB-101
Feb 14
4:37pm ET
Mustang Bio Evaluates Sale of Facility Amid Security Reviews
Jan 07
5:40am ET
BTIG Sticks to Its Buy Rating for Mustang Bio (MBIO)
Jan 02
9:31am ET
BTIG Sticks to Its Buy Rating for Mustang Bio (MBIO)
Dec 31
5:19am ET
Mustang Bio (MBIO) Gets a Buy from BTIG
No recent press releases are available for MBIO
MBIO Financials
Key terms
Ad Feedback
MBIO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MBIO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range